ID: ALA3143519

Max Phase: Preclinical

Molecular Formula: C31H43N5O5

Molecular Weight: 565.72

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCC(C)Oc1ccc(C[C@@H]2NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)CCCCNC(=O)CCNC2=O)cc1

Standard InChI:  InChI=1S/C31H43N5O5/c1-3-21(2)41-24-14-12-23(13-15-24)20-27-30(39)34-18-16-28(37)33-17-8-7-11-26(31(40)36-27)35-29(38)25(32)19-22-9-5-4-6-10-22/h4-6,9-10,12-15,21,25-27H,3,7-8,11,16-20,32H2,1-2H3,(H,33,37)(H,34,39)(H,35,38)(H,36,40)/t21?,25-,26-,27-/m0/s1

Standard InChI Key:  IFBIJTQXNNVYIS-UUKVKESOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 565.72

Molecular Weight (Monoisotopic): 565.3264

AlogP: 1.75

#Rotatable Bonds: 9

Polar Surface Area: 151.65

Molecular Species: NEUTRAL

HBA: 6

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 11.18

CX Basic pKa: 7.71

CX LogP: 1.84

CX LogD: 1.36

Aromatic Rings: 2

Heavy Atoms: 41

QED Weighted: 0.31

Np Likeness Score: 0.22

References

1. Haramura M, Okamachi A, Tsuzuki K, Yogo K, Ikuta M, Kozono T, Takanashi H, Murayama E..  (2002)  Design and synthesis of motilin antagonists derived from the [1-4] fragment of porcine motilin.,  45  (3): [PMID:11806718] [10.1021/jm010332u]

Source

Source(1):

• Scientific Literature